Clinical Trial Update: Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant PRRT with 177Lu-DOTATATE followed by surgery for resectable pancreatic neuroendocrine tumors (PanNET).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)

Snippet

Sponsor: IRCCS San Raffaele | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED